MVK and mevalonic aciduria: The antibody was approved in 2016 for three types of spontaneous inflammatory diseases: tumor necrosis factor receptor associated periodic syndrome (TRAPS), hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase (MKD), and familial Mediterranean fever (FMF) (66).